ESR1 and cancer: In 2015, an interesting finding from the study of Chan (2015) suggested that this subtype might arise from the failure of anti-ER antibody to bind ER, which was caused by structural changes due to genetic mutations (Chan et al., 2015), although it might be simply ascribed not to the genetic change of cancer cells but rather to technical error.